BioSpace News Archive

Envisagenics today announced a research collaboration agreement with Bristol Myers Squibb (NYSE: BMY).

Rallybio Corporation today announced that company management will participate in a virtual fireside chat at the JMP Securities Hematology and Oncology Summit on Wednesday, December 7, 2022, at 1:40 p.m. ET.

Novocure (NASDAQ: NVCR) today announced that Health Canada has approved Optune® for the treatment of newly diagnosed and recurrent glioblastoma (GBM).

Eikonoklastes Therapeutics and Forge Biologics today announced a manufacturing partnership that will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).

Agilent Technologies Inc. announced the deployment of the next generation of alarm resolution technology for checkpoints throughout London Heathrow airport, delivering advanced security and efficiency.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma was awarded oral and poster presentations at World Antiviral Congress 2022.

NanoVibronix, Inc. today announced that it has entered into a securities purchase agreement with several institutional investors for the purchase and sale, in a registered direct offering priced at-the-market under Nasdaq rules, of 4,800,000 shares of its common stock.

Nanomix Corporation (OTCQB: NNMX) (“Nanomix” or the “Company”), a leader in the development of mobile, affordable, point-of-care (POC) diagnostics, today announced that it has entered into a distribution agreement with Gepa Srl (“Gepa”), a distributor and supplier of diagnostic products in Italy.

AmyriAD Therapeutics (AmyriAD) a privately held, late clinical-stage pharmaceutical development company focused on advancing therapies for Alzheimer’s disease (AD), today announced that it will present data on their lead candidate AD101 at the 15th Clinical Trials on Alzheimer’s Disease Conference (CTAD) on November 29 – December 2 in San Francisco, CA.

Vergent Bioscience Awarded National Cancer Institute Phase 2 Grant to Advance Clinical Development of VGT-309 in Lung Cancer.